33.75

0.03% 0.010

After Hours: 33.75

Structure Therapeutics Inc Adr (GPCR)

Overview News Price History Option Chain Financials Why GPCR Down? Discussions Forecast

Structure Therapeutics Inc Adr stock is traded at $33.75, with a volume of 519.64K. It is up +0.03% in the last 24 hours and down -10.22% over the past month. Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Previous Close:

$33.74

Open:

$34

24h Volume:

519.64K

Relative Volume:

0.72

Market Cap:

$1.93B

Revenue:

Net Income/Loss:

$-100.44M

P/E Ratio:

-15.71

EPS:

-2.1478

Net Cash Flow:

$-105.32M

1W Performance:

+3.18%

1M Performance:

-10.22%

6M Performance:

-8.93%

1Y Performance:

-35.59%

1-Day Range:

$33.08

$34.24

1-Week Range:

$29.60

$35.31

52-Week Range:

$26.61

$66.38

Structure Therapeutics Inc Adr Stock (GPCR) Company Profile

Name

Structure Therapeutics Inc Adr

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(628) 229-9277

Address

611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO

Employee

148

Twitter

Next Earnings Date

Latest SEC Filings

GPCR's Discussions on Twitter

Compare GPCR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GPCR Structure Therapeutics Inc Adr	33.75	1.93B	0	-100.44M	-105.32M	-2.1478
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-23-24	Initiated	Morgan Stanley	Overweight
May-21-24	Initiated	JP Morgan	Overweight
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	JMP Securities	Mkt Outperform
Jul-27-23	Initiated	Piper Sandler	Overweight
May-25-23	Resumed	Jefferies	Buy
Feb-28-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	Guggenheim	Buy
Feb-28-23	Initiated	Jefferies	Buy
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Structure Therapeutics Inc Adr Stock (GPCR) Latest News

Nov 23, 2024

Structure Therapeutics (NASDAQ:GPCR) Trading Up 9.3%Time to Buy? - MarketBeat

Nov 23, 2024

Nov 22, 2024

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? - MSN

Nov 22, 2024

Nov 20, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Nov 20, 2024

Nov 19, 2024

Assetmark Inc. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

Nov 19, 2024

Nov 18, 2024

What is Lifesci Capital's Estimate for GPCR FY2024 Earnings? - MarketBeat

Nov 18, 2024

FY2024 Earnings Forecast for GPCR Issued By Lifesci Capital - Defense World

Nov 18, 2024

Nov 17, 2024

GPCRStructure Therapeutics Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 17, 2024

Nov 16, 2024

Structure Therapeutics (NASDAQ:GPCR) Trading Down 8.9%Here's What Happened - MarketBeat

Nov 16, 2024

Nov 15, 2024

Structure Therapeutics to Present at Jefferies London Healthcare Conference | GPCR Stock News - StockTitan

Nov 15, 2024

Nov 14, 2024

GSA Capital Partners LLP Purchases Shares of 30,464 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Nov 14, 2024

Nov 13, 2024

Structure Therapeutics Reports Strong Q3 2024 Results - TipRanks

Nov 13, 2024

Structure Therapeutics Advances Obesity Drug Trial, Reports $915M Cash Position | GPCR Stock News - StockTitan

Nov 13, 2024

Structure Therapeutics Launches Phase 2b Obesity Drug Trial, Expands Testing to Higher Doses | GPCR Stock News - StockTitan

Nov 13, 2024

Nov 05, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World

Nov 05, 2024

Is Viking Therepautics a Buy Now? - MSN

Nov 05, 2024

Oral Proteins and Peptides Market to Reach $28.17 Billion by 2031 As Revealed In New Report - WhaTech

Nov 05, 2024

Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic

Nov 05, 2024

Nov 04, 2024

Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug - MedCity News

Nov 04, 2024

Nov 03, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Position Increased by abrdn plc - MarketBeat

Nov 03, 2024

Nov 01, 2024

Ballard Power Systems Inc (NASDAQ: BLDP) Has Great Upside Potential - Stocks Register

Nov 01, 2024

Is Structure Therapeutics Inc ADR (NASDAQ: GPCR) A Good Investment For New Investors Now? - Stocks Register

Nov 01, 2024

Oct 31, 2024

Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21 - Business Wire

Oct 28, 2024

Oct 26, 2024

Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80 - MarketBeat

Oct 26, 2024

Oct 24, 2024

GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive

Oct 24, 2024

Oct 17, 2024

Griffin Asset Management Inc. Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Oct 17, 2024

Oct 16, 2024